Opinion/decision on a Paediatric investigation plan (PIP): Aspaveli, Pegcetacoplan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: P/0030/2024

Opinion/decision on a Paediatric investigation plan (PIP): Aspaveli, Pegcetacoplan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: P/0030/2024

Finding clinical trials with the ACT EU Trial Map, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 7 March 2025, 13:30 (CET) to 7 March 2025, 14:30 (CET)

Finding clinical trials with the ACT EU Trial Map, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 7 March 2025, 13:30 (CET) to 7 March 2025, 14:30 (CET)

Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate,vilanterol, Date of authorisation: 02/05/2014, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate,vilanterol, Date of authorisation: 02/05/2014, Revision: 25, Status: Authorised

European Shortages Monitoring Platform (ESMP) training on crisis and MSSG-led preparedness reporting for marketing authorisation holders (MAHs), Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 19 February 2025, 10:00 (CET) t

European Shortages Monitoring Platform (ESMP) training on crisis and MSSG-led preparedness reporting for marketing authorisation holders (MAHs), Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 19 February 2025, 10:00 (CET) to 19 February 2025, 12:30 (CET)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness